Literature DB >> 15698775

Synthesis and biodistribution of [(11)C]R116301, a promising PET ligand for central NK(1) receptors.

M Van der Mey1, C G M Janssen, F E Janssens, M Jurzak, X Langlois, F M Sommen, B Verreet, A D Windhorst, J E Leysen, J D M Herscheid.   

Abstract

N1-(2,6-Dimethylphenyl)-2-(4-{(2R,4S)-2-benzyl-1-[3,5-di(trifluoromethyl)[carbonyl-(11)C]benzoyl]hexahydro-4-pyridinyl}piperazino)acetamide ([(11)C]R116301) was prepared and evaluated as a potential positron emission tomography (PET) ligand for investigation of central neurokinin(1) (NK(1)) receptors. 1-Bromo-3,5-di(trifluoromethyl)benzene was converted in three steps into 3,5-di(trifluoromethyl)[carbonyl-(11)C]benzoyl chloride, which was reacted with N1-(2,6-dimethylphenyl)-2-{4-[(2R,4S)-2-benzylhexahydro-4-pyridinyl]piperazino}acetamide providing [(11)C]R116301 in 45-57% decay-corrected radiochemical yield. The total synthesis time, from end of bombardment (EOB) to the formulated product, was 35 min. Specific activity (SA) was 82-172 GBq/micromol (n=10) at the end of synthesis. N1-([4-(3)H]-2,6-Dimethylphenyl)-2-(4-{(2R,4S)-2-benzyl-1-[3,5-di(trifluoromethyl)benzoyl]hexahydro-4-pyridinyl}piperazino)acetamide ([(3)H]R116301) was also synthesized (SA: 467 GBq/mmol). The B(max) for [(3)H]R116301 measured in vitro on Chinese hamster ovary cell membranes stably transfected with the human NK(1) receptor was 19.10+/-1.02 pmol/mg protein with an apparent dissociation constant of 0.08+/-0.01 nM. Ex vivo, in vivo and in vitro autoradiography studies with [(3)H]R116301 in gerbils demonstrated a preferential accumulation of the radioactivity in the striatum, olfactory tubercule, olfactory bulb and locus coeruleus. In vivo, the biodistribution of [(11)C]R116301 in gerbils revealed that the highest initial uptake is in the lung, followed by the liver and kidney. In the brain, maximum accumulation was found in the olfactory tubercules (1.10+/-0.08 injected dose (ID)/g 20 min post injection (p.i.)) and the nucleus accumbens (1.00+/-0.12ID/g 10 min p.i.). Tissue/cerebellum concentration ratios for striatum and nucleus accumbens increased with time due to rapid uptake followed by a slow wash out (1.29 and 1.64, respectively, 30 min p.i.). A tissue to cerebellum ratio of 1.33 and 1.62 was also observed for olfactory bulb and olfactory tubercules, respectively (20 min p.i.). In summary, [(11)C]R116301 appears to be a promising radioligand suitable for the visualization of NK(1) receptors in vivo using PET.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698775     DOI: 10.1016/j.bmc.2004.12.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists.

Authors:  Toshiki Kobayashi; Yuki Furusawa; Shoya Yamada; Masaru Akehi; Fumiaki Takenaka; Takanori Sasaki; Akiya Akahoshi; Takahisa Hanada; Eiji Matsuura; Hiroyuki Hirano; Akihiro Tai; Hiroki Kakuta
Journal:  ACS Med Chem Lett       Date:  2015-01-20       Impact factor: 4.345

2.  [carbonyl-C]Benzyl acetate: automated radiosynthesis via Pd-mediated [C]carbon monoxide chemistry and PET measurement of brain uptake in monkey.

Authors:  Shuiyu Lu; Jinsoo Hong; Tetsuji Itoh; Masahiro Fujita; Osamu Inoue; Robert B Innis; Victor W Pike
Journal:  J Labelled Comp Radiopharm       Date:  2010-06-30       Impact factor: 1.921

Review 3.  The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.

Authors:  Agnieszka Majkowska-Pilip; Paweł Krzysztof Halik; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

4.  First evaluation of [11C]R116301 as an in vivo tracer of NK1 receptors in man.

Authors:  Saskia P A Wolfensberger; Bart N M van Berckel; Anu J Airaksinen; Kaoru Maruyama; Mark Lubberink; Ronald Boellaard; William D H Carey; Wieb Reddingius; Dick J Veltman; Albert D Windhorst; Josée E Leysen; Adriaan A Lammertsma
Journal:  Mol Imaging Biol       Date:  2009-03-31       Impact factor: 3.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.